ACAMPROSATE CALCIUM | A202229 | GLENMARK PHARMACEUTICALS LTD
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Citizen Petition from RegCon Solutions FDA-2015-P-1669 · 6 docket documents RegCon Solutions filed this citizen petition under Section 505(j) of the Federal Food, Drug, and Cosmetic Act requesting that the FDA amend the Orange Book to designate Glenmark Generics' Acamprosate Calcium Delayed Release Tablets (ANDA 202229) as a second reference-listed drug, citing that the cur | 505(q) | 2015-05-13 | Granted | RegCon Solutions |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.6077
per ea
Lowest NADAC/Unit
$0.6077
per ea
Brand NDCs
0
Generic NDCs
3
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 00904721304ACAMPROSATE CALC DR 333 MG TAB | $0.6077 | EA | Generic | — | 2026-06-17 |
| 68462043518ACAMPROSATE CALC DR 333 MG TAB | $0.6077 | EA | Generic | — | 2026-06-17 |
| 60687012125ACAMPROSATE CALC DR 333 MG TAB | $0.6077 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.